We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC Expands Women's Health Portfolio With AI-Enabled Voluson
Read MoreHide Full Article
Key Takeaways
{\"0\":\"GEHC launched Voluson Performance 18 and 16 to advance maternal and reproductive care.\",\"1\":\"GEHC\'s new AI-driven tools cut exam time by up to 75% and improve imaging precision.\",\"2\":\"GEHC\'s Voluson systems earned FDA and CE approvals, supporting global rollout later this year.\"}
GE HealthCare (GEHC - Free Report) recently unveiled the Voluson Performance 18 and 16, the latest generation of ultrasound systems in its women’s health portfolio. The launch underscores the company’s commitment to advancing maternal and reproductive care through artificial intelligence (AI), automation, and intuitive design, aiming to enhance diagnostic precision and workflow efficiency for clinicians worldwide.
The Voluson Performance series builds on the legacy of the Voluson platform, a trusted name in women’s health imaging. By combining high-resolution imaging with smart automation, the new systems are designed to enable clinicians to perform scans more quickly and confidently. This innovation comes at a time when maternal mortality remains a critical challenge, with an estimated 700 women dying daily from maternal causes globally, highlighting the urgent need for advanced diagnostic solutions.
The new systems have received FDA 510(k) clearance and CE Mark approval, paving the way for global rollout. GE HealthCare will showcase the Voluson Performance series at the 35th ISUOG World Congress on Ultrasound in Obstetrics and Gynecology, held during Sept. 14-17 in Cancun, Mexico. Availability will begin in key international markets later this year.
Likely Trend of GEHC Stock Following the News
Shares of GE HealthCare have lost 0.9% so far this year against the industry’s growth of 5.4%. The S&P 500 Index has increased 13.5% in that period.
Image Source: Zacks Investment Research
The launch of the Voluson Performance series is expected to reinforce GE HealthCare’s leadership in women’s health imaging, a strategically important segment in diagnostic care. Investors may view this move as a way to strengthen the company’s precision care strategy while expanding its addressable market in maternal and reproductive health. With FDA clearance and CE Mark approval, early adoption in key geographies could translate into incremental revenue streams.
While near-term stock movement may hinge on broader market conditions, the announcement is likely to be perceived positively, supporting GEHC’s long-term growth narrative and potentially bolstering investor confidence.
Voluson’s New Features
Key innovations in the new systems include Autolive, which automatically adjusts gain to improve image uniformity, and Shadow Reduction, which enhances image clarity across exams. The technology is also supported by a comprehensive probe portfolio for 2D and 3D imaging, integrated wireless Vscan Air probes for bedside use, and an updated touch interface with a voice-activated “Hey Voluson” feature for streamlined, hands-free control. Together, these features are designed to reduce keystrokes, simplify workflows, and minimize user fatigue.
The AI-driven SonoLyst suite stands out as a transformative tool in the Voluson Performance series. It identifies fetal anatomy in standard views, annotates images automatically, and reduces the keystrokes required for routine second-trimester examinations by up to 65%.
In addition, SonoPelvicFloor, another embedded AI solution, offers guided workflows that can deliver exam results up to 75% faster, enabling clinicians to achieve consistent, reproducible outcomes. These advancements are expected to benefit clinicians across varying levels of expertise, making complex imaging more accessible and efficient.
By embedding intelligent tools within its ultrasound systems, GE HealthCare aims to address growing pressures on healthcare systems for accuracy, speed, and accessibility. The design of the Voluson Performance 18 and 16 not only enhances clinical decision-making but also expands access to high-quality imaging for women in diverse care settings.
Currently, GEHC sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, currently sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GEHC Expands Women's Health Portfolio With AI-Enabled Voluson
Key Takeaways
GE HealthCare (GEHC - Free Report) recently unveiled the Voluson Performance 18 and 16, the latest generation of ultrasound systems in its women’s health portfolio. The launch underscores the company’s commitment to advancing maternal and reproductive care through artificial intelligence (AI), automation, and intuitive design, aiming to enhance diagnostic precision and workflow efficiency for clinicians worldwide.
The Voluson Performance series builds on the legacy of the Voluson platform, a trusted name in women’s health imaging. By combining high-resolution imaging with smart automation, the new systems are designed to enable clinicians to perform scans more quickly and confidently. This innovation comes at a time when maternal mortality remains a critical challenge, with an estimated 700 women dying daily from maternal causes globally, highlighting the urgent need for advanced diagnostic solutions.
The new systems have received FDA 510(k) clearance and CE Mark approval, paving the way for global rollout. GE HealthCare will showcase the Voluson Performance series at the 35th ISUOG World Congress on Ultrasound in Obstetrics and Gynecology, held during Sept. 14-17 in Cancun, Mexico. Availability will begin in key international markets later this year.
Likely Trend of GEHC Stock Following the News
Shares of GE HealthCare have lost 0.9% so far this year against the industry’s growth of 5.4%. The S&P 500 Index has increased 13.5% in that period.
Image Source: Zacks Investment Research
The launch of the Voluson Performance series is expected to reinforce GE HealthCare’s leadership in women’s health imaging, a strategically important segment in diagnostic care. Investors may view this move as a way to strengthen the company’s precision care strategy while expanding its addressable market in maternal and reproductive health. With FDA clearance and CE Mark approval, early adoption in key geographies could translate into incremental revenue streams.
While near-term stock movement may hinge on broader market conditions, the announcement is likely to be perceived positively, supporting GEHC’s long-term growth narrative and potentially bolstering investor confidence.
Voluson’s New Features
Key innovations in the new systems include Autolive, which automatically adjusts gain to improve image uniformity, and Shadow Reduction, which enhances image clarity across exams. The technology is also supported by a comprehensive probe portfolio for 2D and 3D imaging, integrated wireless Vscan Air probes for bedside use, and an updated touch interface with a voice-activated “Hey Voluson” feature for streamlined, hands-free control. Together, these features are designed to reduce keystrokes, simplify workflows, and minimize user fatigue.
The AI-driven SonoLyst suite stands out as a transformative tool in the Voluson Performance series. It identifies fetal anatomy in standard views, annotates images automatically, and reduces the keystrokes required for routine second-trimester examinations by up to 65%.
In addition, SonoPelvicFloor, another embedded AI solution, offers guided workflows that can deliver exam results up to 75% faster, enabling clinicians to achieve consistent, reproducible outcomes. These advancements are expected to benefit clinicians across varying levels of expertise, making complex imaging more accessible and efficient.
By embedding intelligent tools within its ultrasound systems, GE HealthCare aims to address growing pressures on healthcare systems for accuracy, speed, and accessibility. The design of the Voluson Performance 18 and 16 not only enhances clinical decision-making but also expands access to high-quality imaging for women in diverse care settings.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, currently sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.11%.